Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: Toxicity, pharmacokinetics, and activity

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1300-1307

  Fu, Siqing ^a   Naing, Aung ^a   Moulder, Stacy L ^a   Culotta, Kirk S ^a   Madoff, David C ^a   Ng, Chaan S ^a   Madden, Timothy L ^a   Falchook, Gerald S ^a   Hong, David S ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; NANOPARTICLE; PACLITAXEL;

ADULT; ADVANCED CANCER; ALOPECIA; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CARCINOID; CLINICAL ARTICLE; COLORECTAL CANCER; CONFUSION; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG UPTAKE; EDEMA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; LEIOMYOSARCOMA; LIVER METASTASIS; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SARCOMA; THROMBOCYTOPENIA; THRUSH; TOXIC EPIDERMAL NECROLYSIS; TUMOR GROWTH; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 79960119359     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0259     Document Type: Article

References (49)

1. Barber FD, Mavligit G, Kurzrock R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 2004;30:425-36. (Pubitemid 38968123)
2. Melichar B, Voboril Z, Cerman J, Melicharová K, Nozicka J, Mergancová J, et al. Hepatic arterial infusion chemotherapy in gastric cancer: a report of four cases and analysis of the literature. Tumori 2004;90:428-34. (Pubitemid 39287244)
3. Sato T. Locoregional immuno(bio)therapy for liver metastases. Semin Oncol 2002;29:160-7. (Pubitemid 34297287)
4. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341: 2039-48. (Pubitemid 30035952)
5. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23:3465-74.
6. Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, et al. Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 2007;13:280-4. (Pubitemid 46231333)
7. Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 2005;103:1402-7. (Pubitemid 40410735)
8. Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004;14: 217-22. (Pubitemid 38879585)
9. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, et al. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 2010;66:1087-93.
10. Neyns B, Van Nieuwenhove Y, Aerts M, Fontaine C, Vermeij J, Schallier D, et al. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Res 2006;26:611-9. (Pubitemid 43206025)
11. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005;23:4881-7. (Pubitemid 46223993)
12. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 2003;23:5203-8. (Pubitemid 38182147)
13. Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001;12:599-603. (Pubitemid 32519910)
14. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, et al. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 2010;116: 4086-94.
15. Tono T, Iwazawa T, Matsui S, Yano H, Kimura Y, Kanoh T, et al. Hepatic arterial infusion of paclitaxel for liver metastasis from gastric cancer. Cancer Invest 2004;22:550-4. (Pubitemid 39506876)
16. Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, et al. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007;109:2190-6. (Pubitemid 46801547)
17. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-95. (Pubitemid 32441374)
18. Berlin J, Merrick HW, Smith TJ, Lerner H. Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). Am J Clin Oncol 1999;22:291-3. (Pubitemid 30263325)
19. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, et al. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994;12:1204-11. (Pubitemid 24173934)
20. Moertel CG. Hepatic arterial floxuridine infusion and patient survival. J Clin Oncol 1992;10:1986-8. (Pubitemid 23064216)
21. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8.
22. Okuno K, Yasutomi M, Hida J, Kayama H, Nakai T, Funai S, et al. Long-term effects of hepatic arterial interleukin-2-based immunochemotherapy after potentially curative resection of colorectal liver metastases. J Am Coll Surg 1998;187:271-5. (Pubitemid 28433434)
23. Yamamoto M, Iizuka H, Fujii H, Matsuda M, Miura K. Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma. Acta Oncol 1993;32:43-51. (Pubitemid 23080772)
24. Qin B, Kato K, Mitsugi K, Nakamura M, Tanaka R, Baba E, et al. Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. Cancer Chemother Pharmacol 2006;57:114-9.
25. Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, et al. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. J Gastroenterol 2007;42:501-6. (Pubitemid 47050015)
26. Pohlen U, Mansmann U, Berger G, Germer CT, Gallkowski U, Boese-Landgraf J, et al. Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. Anticancer Res 2004;24:3275-82. (Pubitemid 39390985)
27. Patt YZ, Hoque A, Lozano R, Pozdur R, Chase J, Carrasco H, et al. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol 1997;15:1432-8. (Pubitemid 27167376)
28. Pohlen U, Rieger H, Mansmann U, Berger G, Buhr HJ. Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patients with non-resectable colorectal liver metastases. Anticancer Res 2006;26:3957-64.
29. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25:5649-54.
30. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403. (Pubitemid 46622004)
31. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res 2005;11: 4136-43. (Pubitemid 40791578)
32. Damascelli B, Cantù G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 2001;92:2592-602. (Pubitemid 33049443)
33. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-93. (Pubitemid 46657375)
34. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13: 176-81. (Pubitemid 36962641)
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
36. Doria MI Jr, Doria LK, Faintuch J, Levin B. Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer 1994;73:2042-7. (Pubitemid 24107955)
37. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44. (Pubitemid 34517637)
38. Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007;60:759-66.
39. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-77.
40. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984;2:498-504. (Pubitemid 14075984)
41. Tse AN, Wu N, Patel D, Haviland D, Kemeny N. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol 2009;64:935-44.
42. Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 2010;40:404-11.
43. Minshall RD, Tiruppathi C, Vogel SM, Niles WD, Gilchrist A, Hamm HE, et al. Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J Cell Biol 2000;150:1057-70.
44. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007;13:345-57. (Pubitemid 47387129)
45. Altundag K, Bulut N, Dizdar O, Harputluoglu H. Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007. Breast Cancer Res Treat 2006;100:329-30.
46. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53. (Pubitemid 43949942)
47. Walton GD, Schreeder MT, Rizzo J, Jobe DR, Kuhn J. Hepatic artery administration of paclitaxel. Cancer Invest 1999;17:118-20. (Pubitemid 29115644)
48. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19: 899-909.
49. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59-64.